B. Riley Predicts Higher Earnings for Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Analysts at B. Riley boosted their FY2025 earnings estimates for Corbus Pharmaceuticals in a research note issued on Thursday, March 13th. B. Riley analyst K. Patel now forecasts that the biopharmaceutical company will post earnings of ($3.70) per share for the year, up from their previous forecast of ($5.60). The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals’ Q4 2025 earnings at ($0.92) EPS, FY2026 earnings at ($3.14) EPS and FY2027 earnings at ($3.27) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings data on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share for the quarter, beating the consensus estimate of ($1.02) by $0.24.

A number of other brokerages have also recently issued reports on CRBP. Wedbush reiterated an “outperform” rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. StockNews.com upgraded shares of Corbus Pharmaceuticals to a “sell” rating in a research report on Thursday, March 6th. Jefferies Financial Group cut their price objective on Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating for the company in a research note on Tuesday, March 11th. William Blair started coverage on Corbus Pharmaceuticals in a report on Friday, February 28th. They set an “outperform” rating on the stock. Finally, Piper Sandler assumed coverage on shares of Corbus Pharmaceuticals in a report on Monday, December 2nd. They issued an “overweight” rating and a $35.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Corbus Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $59.13.

Corbus Pharmaceuticals Stock Performance

Corbus Pharmaceuticals stock opened at $6.79 on Monday. The stock has a market cap of $82.70 million, a price-to-earnings ratio of -1.45 and a beta of 2.63. The stock’s 50 day simple moving average is $9.44 and its two-hundred day simple moving average is $18.46. Corbus Pharmaceuticals has a fifty-two week low of $6.38 and a fifty-two week high of $61.90.

Hedge Funds Weigh In On Corbus Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Vestcor Inc acquired a new position in Corbus Pharmaceuticals in the 3rd quarter valued at $64,000. JPMorgan Chase & Co. boosted its holdings in Corbus Pharmaceuticals by 27.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 1,172 shares during the period. MetLife Investment Management LLC purchased a new stake in Corbus Pharmaceuticals during the 3rd quarter worth approximately $123,000. Wells Fargo & Company MN boosted its holdings in Corbus Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 6,444 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 2,195 shares during the period. Finally, Avanza Fonder AB purchased a new position in Corbus Pharmaceuticals in the fourth quarter worth approximately $84,000. Institutional investors and hedge funds own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.